Rheumatology Network interviewed Theodore Fields, MD, FACP, rheumatologist at HSS to discuss the top highlights of gout in the year 2022.

Dr. Fields discussed stand out studies, including the MIRROR trial, a study pinpointing the role of lubricin deficiency in the pathogenesis of gout, and a Korean study that compared febuxostat and allopurinol treatment and the impact they had on adverse cardiovascular reactions. He went on to discuss regulatory news updates and issues that he hopes will be addressed in 2023, including continued education of the physician community about the patient benefit from an aggressive and targeted approach. 

Read the full article at rheumatologynetwork.com.